Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04285398 · ClinicalTrials.gov registry record · NA
Prospective Natural History Study of Retinitis Pigmentosa
A NA study of Retinitis Pigmentosa, sponsored by SparingVision.
- Active
- Registry status
- NA
- Development phase
- 82
- Enrollment target
- 2
- Study locations
NCT04285398: Active NA study of Retinitis Pigmentosa, sponsored by SparingVision.
NCT04285398 is a NA study of Retinitis Pigmentosa that is active but no longer recruiting, run by SparingVision. The registered enrollment target is 82 participants, below the 259-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04285398, a NA study of Retinitis Pigmentosa, is active but no longer recruiting, sponsored by SparingVision.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.
Primary Outcome
Progression of disease over time as measured by SD-OCT (EZ length, ELM length, ONL thickness, macular volume).
Conditions Studied
Interventions
- OTHER Ophthalmic examinations
- OTHER Mobility Test
Study Locations (2)
Pennsylvania
- UPMC Eye Center - Pittsburgh
Other
- CHNO XV-XX Paris - CIC 1423 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT04285398 still lists
NCT04285398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 259-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Ophthalmic examinations is the first listed.
NCT04285398 reports a single indexed study location in Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT04285398 about?
NCT04285398 is a clinical study titled "Prospective Natural History Study of Retinitis Pigmentosa". This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.
What is the current status of trial NCT04285398?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 82 participants. The study started on 2020-02-12. Estimated completion is 2026-06-30.
What conditions does trial NCT04285398 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT04285398?
The interventions under investigation include: Ophthalmic examinations (OTHER), Mobility Test (OTHER).
Who is sponsoring clinical trial NCT04285398?
This trial is sponsored by SparingVision, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04285398 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04285398's enrollment target sits among peer trials
82 14th of 37 higher than 24 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Experimental and Clinical Studies of Retinal Stimulation
RECRUITING · NA
-
Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa
ACTIVE NOT RECRUITING · NA
-
Argus II/ORCAM Device Study
COMPLETED · NA
-
Object Finder for a Retinal Prosthesis
COMPLETED · NA
-
Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI